Skip to content
Clinical Trials – home

AZ Sint-Lucas & Volkskliniek

Research site

Belgium Groenebriel 1, 9000 Gent, Belgium

  • 24 trials recruiting
  • Colitis ulcerative · Crohn's disease · Arteriosclerosis
  • Adults and children

About Specializations

AZ Sint-Lucas & Volkskliniek in Gent, Belgium specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Arteriosclerosis, Hidradenitis, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive and Immune-Mediated Diseases

At AZ Sint-Lucas & Volkskliniek, clinical research in gastro-enterology focuses strongly on digestive system diseases and immune system diseases, especially Crohn's disease, ulcerative colitis, and other forms of inflammatory bowel disease. These studies are mainly designed to improve disease control, reduce relapse, and find better long-term treatment strategies for patients with chronic intestinal inflammation.

  • Therapeutic focus on Digestive System Diseases and Immune System Diseases
  • Main conditions include Crohn's disease, ulcerative colitis, and inflammatory bowel disease type unclassified
  • Trials aim to improve symptom control, maintain remission, and prevent postoperative recurrence

The site is also involved in studies evaluating new biologic and immune-targeted approaches for patients who have not responded well to standard care.

Cardiovascular and Metabolic Research

Another major area of research at the site covers cardiovascular diseases and nutritional and metabolic diseases. The trials include people with heart failure, atherosclerotic cardiovascular disease, hypertension, and chronic kidney disease in type 2 diabetes mellitus. The overall goal is to test new ways to lower cardiovascular risk, improve heart function, and slow disease progression in patients with complex cardiometabolic conditions.

  • Key fields: Cardiovascular Diseases and Nutritional and Metabolic Diseases
  • Conditions studied include heart failure, hypertension, and atherosclerotic cardiovascular disease
  • Research aims to reduce major cardiovascular events and improve long-term outcomes

These studies reflect a broad effort to address both prevention and treatment in patients at elevated cardiovascular risk.

Oncology and Advanced Cancer Care

The site also supports a wide range of cancer studies across neoplasms, with a particular emphasis on breast cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer, and urothelial carcinoma. These trials are generally focused on testing new treatment combinations, extending disease control, and improving outcomes for patients with advanced or recurrent cancers.

  • Therapeutic area: Neoplasms
  • Main cancers include breast cancer, ovarian cancer, prostate cancer, lung cancer, and colorectal cancer
  • Research aims to improve survival, delay progression, and refine treatment options for advanced disease

At AZ Sint-Lucas & Volkskliniek, oncology research spans both common and difficult-to-treat tumors, with studies often centered on better disease control after standard therapy.

Autoimmune, Skin, and Neuromuscular Disorders

Clinical trials at this hospital also explore immune system diseases, skin and connective tissue diseases, and nervous system diseases. The research includes atopic dermatitis, hidradenitis suppurativa, myasthenia gravis, amyotrophic lateral sclerosis, and multifocal motor neuropathy. These studies are intended to evaluate new therapies that may relieve symptoms, improve function, and support longer-term disease management.

  • Focus areas include Immune System Diseases, Skin and Connective Tissue Diseases, and Nervous System Diseases
  • Conditions studied include atopic dermatitis, hidradenitis suppurativa, myasthenia gravis, and amyotrophic lateral sclerosis
  • Trials aim to improve symptom relief, disease stability, and patient quality of life

These investigations show a strong interest in both chronic inflammatory skin disease and rare neurological conditions.

Respiratory, Infectious, and Other Specialized Studies

Beyond its main specialty areas, the site participates in studies on bacterial infections and mycoses, environment and public health, and several other complex conditions. Examples include critically ill patients with infection, eosinophilic esophagitis, infertility, and transthyretin amyloidosis with cardiomyopathy. These trials are aimed at improving treatment effectiveness, refining care pathways, and addressing unmet needs across a diverse patient population.

  • Broader research spans Bacterial Infections and Mycoses and Environment and Public Health
  • Includes studies in eosinophilic esophagitis, infectious disease, infertility, and amyloidosis
  • Purpose is to improve care quality, treatment effectiveness, and clinical outcomes in specialized settings

The diversity of topics highlights the site’s role in both routine and highly specialized clinical research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Groenebriel 19000 GentBelgium
Recruiting now
24 trials
Conditions studied
54

More sites in GentBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

71 clinical trials

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:BioNTech SE

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.